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Abstract: Epigenetic modifications play an important role in lymphoid malignancies. This 
has been evidenced by the large body of work published using microarray technologies to 
generate methylation profiles for numerous types and subtypes of lymphoma and leukemia. 
These studies have shown the importance of defining the epigenome so that we can better 
understand the biology of lymphoma. Recent advances in DNA sequencing technology 
have transformed the landscape of epigenomic analysis as we now have the ability to 
characterize the genome-wide distribution of chromatin modifications and DNA 
methylation using next-generation sequencing. To take full advantage of the throughput of 
next-generation sequencing, there are many methodologies that have been developed and 
many more that are currently being developed. Choosing the appropriate methodology is 
fundamental to the outcome of next-generation sequencing studies. In this review, 
published technologies and methodologies applicable to studying the methylome are 
presented. In addition, progress towards defining the methylome in lymphoma is discussed 
and prospective directions that have been made possible as a result of next-generation 
sequencing technology.  Finally, methodologies are introduced that have not yet been 
published but that are being explored in the pursuit of defining the lymphoma methylome. 
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1. Introduction 
The human genome is comprised of three billion base pairs of DNA, of which ~30 million are CpG 
dinucleotides, the main sites of DNA methylation.  Methylation of cytosine residues at CpG 
dinucleotides is a prevalent epigenetic modification in mammalian genomes which is known to have 
profound effects on gene expression [1-3]. This epigenetic event occurs globally in the normal genome 
and is estimated to affect between 70 and 80% of all CpG dinucleotides in human cells [4,5]. These 
dinucleotides are not uniformly distributed across the genome but occur in clusters such as large 
repetitive sequences or in CG-rich DNA stretches known as CpG islands (CGIs). The majority of the 
CGI which are found in intragenic regions, including repetitive sequences such as satellite sequences 
and centromeric repeats, contain methylated CpG dinucleotides while CGIs which are found 
preferentially in the promoter regions of genes typically contain unmethylated CpG dinucleotides [6]. 
Some exceptions to this rule include those CGIs located on the inactive X chromosome in females [7] 
and those associated with imprinted genes (genes for which only the paternally-  or maternally-
inherited allele is expressed) which are methylated in the normal state [8,9]. Contrary to normal cells, a 
number of studies examining DNA methylation in human cancers have shown global hypomethylation 
and concomitant hypermethylation in the regulatory regions of specific genes [10,11], although this 
concept has recently been challenged [12]. Methylation of DNA in humans is generally thought to take 
place via some combination of three  DNA methyltransferase enzymes (DNMT1, DNMT3A, and 
DNMT3B).  Whereas DNMT1 is  responsible for the  maintenance of normal methylation patterns, 
DNMT3A and 3B are primarily associated with de novo methylation. Large-scale studies of DNA 
methylation have shown that aberrant methylation is a phenomenon present in virtually all types of 
tumors but it occurs in a generally non-random manner that differs between tumor types. Exactly how 
the methylation is directed and controlled is still a largely unanswered question. Polycomb group 
(PcG) proteins are likely to be key in marking certain genes for DNA methylation and in altering 
histone methylation leading to the formation of repressive chromatin, but the mechanisms by which 
this occurs are not completely elucidated [13-18]. A class of non-coding RNAs, the microRNAs, are 
also likely modulators of DNA methylation. It has been suggested that miR-143 controls DNMT3A in 
colorectal cancer [19] and that the miR-29 family regulates DNMT3A and 3B in lung cancer [20]. 
Furthermore, miR-29b has recently been shown to target all three DNA methyltransferase genes either 
directly or indirectly in acute myeloid leukemia [21]. 
A number of methods have been used to examine DNA methylation at whole- or sub-genome scale, 
and over time these methods have progressed from the ability to characterize the methylation profiles 
of candidate genes to the ability to develop genome-wide methylation profiles (Figure 1). These have 
been discussed in detail in an excellent review by Peter Laird [22]. Generally, these can be categorized 
into the preparative method and the analytical or detection systems employed.  The preparative 
methods typically fall into three broad classes that include enzyme digestions, affinity enrichments, or 
treatment with sodium bisulfite while the detection systems can be described as locus-specific, gel-
based, array-based, or as discussed below, next-generation sequencing (NGS) based methods. 
Although none of these earlier methods is perfect, each has allowed contributions of valuable 
epigenetic data to the scientific community from a large number of laboratories. In the advent of next 
generation sequencing, we now have the ability to detect aberrant epigenetic events in cancer at high Genes 2010, 1                              
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resolution. This review describes the technologies and methods currently being used to develop high 
resolution methylation profiles and the progress that has been made using NGS to characterize the 
methylome in lymphoma. 
Figure 1. Time versus number of loci assayed. The number of loci assayed has increased 
over time with the development of new technologies.  Bisulfite sequencing (BS), 
methylation specific PCR (MSP) and combined bisulfite restriction analysis (COBRA) 
were introduced in the 1990s. These methods provided methylation data for up to a few 
hundred genes in a single experiment. Methylation arrays were introduced in the 2000s and 
provide methylation data for up to 100s of thousands of loci. (N.B.  The  latest 
oligonucleotide array available from Nimblegen allows for the interrogation of more than  
two million loci). Next-generation sequencing (NGS) was introduced in 2007 and provides 
single base pair resolution for billions of nucleotides.  
 
 
2. Cutting-edge Technological Advances 
In a relatively short time period, since its inception in 2007, the power of NGS technology has 
transformed the science of genomic research. Currently, five commercial NGS platforms are available; 
however,  Roche/454 (Branford, CT), Illumina/Solexa (San Diego, CA), and Applied 
Biosystems/SOLiD
TM (Carlsbad, CA), dominate the sequencing market shares. Additional platforms 
such as Pacific Biosciences (Menlo Park, CA), are on the horizon. A feature that all NGS platforms 
share is the parallel sequencing of clonally amplified or single DNA molecules that are immobilized on 
an array or flow cell. This feature fundamentally sets NGS apart from conventional capillary-based 
sequencing in that millions of sequence reads can be generated in parallel rather than 96 at a time. The 
significant increase in throughput has lead to a dramatic reduction in sequencing cost and a massive 
accumulation of genomic sequences. The Human Genome Project which was completed in 2003 by Genes 2010, 1                              
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Sanger sequencing took 13 years to complete and cost approximately $2.7 trillion dollars. Now, in 
2010, a human genome can be sequenced in eight days with 30x coverage for approximately $10,000 
dollars using the latest HiSeq2000 sequencer from Illumina. The NGS platforms have facilitated many 
novel sequencing applications, particularly in the area of epigenomic research. For example, in 2009, 
the first human epigenome was sequenced using NGS [23]. Although all NGS platforms share some 
common features, they also differ significantly. (See [24] for an in depth review of the sequencing 
technologies and a comparison of current specifications). These differences will affect the applications 
of each platform and the challenges of bioinformatic analysis as described below. 
2.1. Roche (454) genome sequencer FLX 
The 454 Genome Sequencer FLX (454 GS FLX) was the first commercially available NGS to 
combine single-molecule emulsion PCR with massively parallel pyrosequencing. The sequencing 
chemistry is based on the principle of pyrosequencing in which a pyrophosphate molecule is released 
upon nucleotide incorporation by DNA polymerase for luminescence detection. The clonal 
amplification of sequencing templates bound on agarose beads is achieved by emulsion PCR which 
uses a vigorously mixed oil and aqueous mixture to create water-in-oil microvesicles. These 
microvesicles serve as micro-bioreactors for the PCR reaction. Under limiting-dilution conditions only 
one bead will be present in each water-in-oil vesicle. Each agarose bead surface contains several 
million copies of the same single stranded sequencing template, while millions of such beads can be 
generated in a matter of hours [25]. The microbeads are enriched and deposited into 3.4 million 
picoliter-scale sequencing reaction wells and combined with sequencing chemistry (See 
http://www.454.com for an explanation of the workflow and technology). Each picotiter plate can be 
divided into 16 portions allowing for the simultaneous sequencing of 2, 4, 8 or 16 samples. Over one 
hundred bar-coded sequencing adaptors are available and therefore up to a thousand samples can be 
multiplexed on one picotiter plate. The biggest advantage of 454’s sequencing technology is the read 
length which is on average 450 bp using the newest “titanium” version compared to 50 to 125 bp read 
lengths generated by the other two major platforms. The longer reads facilitate de novo assembly for 
certain sequencing applications. About 1GB of data from one million sequencing reads can  be 
generated in a single seven hour run on the 454 GS FLX as opposed to a multiple day run on both the 
Illumina GA and ABI SOLiD
TM platforms. However, the Illumina GA, and ABI SOLiD
TM sequencers 
produce approximately 100 million reads per run. Therefore, the sequencing cost per base is higher 
with the 454 GS FLX. The 454 GS FLX was also the first NGS platform to be used for epigenetic 
studies. The 454 website currently lists 23 publications in the field of epigenetics and of these four 
used bisulfite sequencing to determine the precise location of CpG methylation in cancer [26-29]. One 
major limitation of the 454 technology is that it is difficult to correctly call homopolymers greater than 
3-4 bases in length. This limitation is exasperated in bisulfite sequencing because in many GC rich 
regions, a long stretch of poly-A or poly-T will appear due to the conversion of unmethylated C to T. 
However, since the bisulfite sequence reads are not assembled but merely aligned to the reference 
genome sequence, modifications to the mapping algorithms can solve this problem. In addition, the 
longer sequencing reads produced by this technology greatly enhances the opportunity for accurate 
alignment of the bisulfite converted  sequences to the reference genome. Approximately  70% of Genes 2010, 1                              
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bisulfite sequencing reads generated by the 454 GS FLX can be mapped accurately to the reference 
genome while there is significant variation reported in the mapping rates using the Illumina GA and 
SOLiD
TM platforms due to the shorter read lengths produced by these technologies [30-32]. 
2.2. Illumina genome analyzer 
The Illumina GA was the first short read NGS platform based on the concept of “sequence-by-
synthesis” (SBS).  It  produces  sequence reads of 36 to 125  bp  from tens of millions of clonally 
amplified DNA fragments on a flow cell. The Illumina technology uses a novel PCR process known as 
bridge PCR to achieve clonal amplification of sequencing templates on the surface of a glass flow cell 
comprised of eight separate lanes. Each lane has covalently attached oligonucleotides that are 
complimentary to specific adaptors that are ligated to the library fragments. Under limiting-dilution 
conditions, adaptor-modified single-stranded  template DNA is hybridized to the  anchor 
oligonucleotides on the flow cell followed by  subsequent cyclic PCR  to convert a single DNA 
molecule into a clonally amplified cluster consisting of approximately 1000 molecules. The Illumina 
sequencing chemistry uses four different fluorescent dye labeled nucleotides and resembles traditional 
Sanger sequencing. However, these nucleotides are modified at the 3’-OH group to ensure that only a 
single nucleotide is incorporated in each sequencing cycle. Each sequencing cycle is followed by an 
imaging step to capture the incorporated nucleotide at each cluster. The fluorescent group is removed 
after imaging and the 3’-end is re-opened for the next base incorporation cycle. Up to 125 cycles can 
be repeated using existing  protocols which generate up to 125  bp  sequence reads  due to the 
improvement of sequencing chemistry and image analysis software. A typical run yields approximately 
70-100 million reads and takes three to six days depending on the read length desired. Because of its 
robust performance and the improvement of read length and accuracy over time, the Illumina GA 
occupies over 60% of the current market. Many different applications have been developed on this 
platform including RNA-seq, small RNA sequencing, ChIP-seq, and whole genome and targeted 
sequencing. The Illumina GA has been used for shotgun whole-genome bisulfite sequencing of human, 
mouse and plant genomes [23,33-35]. Also, a method known as targeted capture bisulfite sequencing 
was developed for the Illumina GA instrument [30,32,36]. In total there are more than 40 epigenetics 
publications using the Illumina GA instrument.  Of these, 17 address DNA methylation and two 
address DNA methylation in cancer [32,37]. Many early bisulfite sequencing experiments produced 
less than 30% mappable reads compared to ~  80-90% mappable reads for non bisulfite-treated 
sequencing using the same short read alignment software [30,32,36]. This discord in mappability is 
due in large part to the limitations of current mapping algorithms to align bisulfite converted 
sequences.  Furthermore,  because  the mapping rate may  vary  significantly between samples, the 
comparability of data may be jeopardized. 
2.3. Applied biosystems (SOLiD
TM) 
The SOLiD
TM (Sequencing by Oligo Ligation and Detection) system was released in 2007 by 
Applied Biosystems and is based on a unique sequencing process called “sequencing by ligation”. The 
approach was initially developed by George Church’s group at Harvard and was  termed polony 
sequencing [38]. Applied Biosystems refined the technology and developed a two color sequencing Genes 2010, 1                              
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chemistry for this instrument. Similar to the 454 system, the SOLiD
TM system also uses emulsion PCR 
to generate clonally amplified sequencing templates. However, much smaller magnetic beads (1 um) 
are used in the emulsion PCR process and the beads are covalently attached to the surface of glass 
slides. With the current SOLiD
TM 4 system, over 700 million reads per run can be achieved for a single 
read library. Each run requires 6-8 days and produces 40-50 GB of data with a read length of 50 bp. In 
addition to genome sequencing, RNA-seq, small RNA sequencing, and ChIP-seq, bisulfite sequencing 
of a bacterial genome has recently been published using this technology [39]. The main advantages of 
this technology are increased throughput and increased sequencing accuracy compared to the other 
sequencing platforms.  
2.4. Other sequencing technologies. 
Helicose is an alternative NGS platform which uses a similar principle to the three major platforms 
but does not rely on clonal amplification. It is the only platform to date that has truly achieved single 
molecule parallel sequencing. However, because of its late entry into the market, and a relatively high 
cost, sales have considerably  lagged behind the three platforms described above. In addition, the 
Polonator has been commercialized by Dover systems and is based on the original polony sequencing 
methods developed by Church’s group [38]. This system is relatively inexpensive but the throughput 
and read lengths are lower than the major commercial platforms; therefore, few laboratories are using 
this system. Complete Genomics, a company based in Mountain View, California, has also published a 
sequencing method [40]. Speed and cost have been Complete Genomics' key selling points. They 
claim that by June of 2010 the cost of materials will be approximately $1,000 per genome. 
2.5. Third generation sequencing technologies. 
In addition to the second generation sequencing platforms mentioned above, third generation 
sequencing platforms are beginning to emerge. For example, Pacific Biosciences uses a single-
molecule technology with engineered DNA polymerase to capture and record the incorporation of 
fluorescently labeled nucleotides into growing complementary nucleic acid strands. While this 
technology produces fewer reads than 454’s GS FLX, Illumina’s  GA and Applied Biosystem’s 
SOLiD
TM,  it is distinguished by its very  long reads and ultra-fast real time sequencing. This 
transformative technology will enable a new paradigm in genomic analysis. Particularly interesting, 
the tempo and duration of the resulting fluorescent  pulses yield a rich set of information about 
polymerase kinetics and allow direct detection of various forms of modified nucleotides, including  
5-methylcytosine, 5-hydroxymethylcytosine, and N6-methyladenosine. Therefore, it is possible to 
detect methylated bases without the need for bisulfite conversion of genomic DNA. Unlike current 
bisulfite-sequencing techniques which are limited by short read lengths and by a reduction in genomic 
complexity, the Pacific Biosciences method will enable mapping of methylation patterns even within 
highly repetitive genomic regions.  
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3. Methylome Methodologies  
Genome-wide methylation methodologies can be divided into those that divulge the precise location 
of methylated CpG dinucleotides (site specific) and those that disclose methylated regions of the 
genome. The site specific methods rely on bisulfite conversion of DNA while the regional methods 
rely on enzyme digestion or the affinity of either antibodies or proteins to methylated DNA. Sodium 
bisulfite converts unmethylated cytosines to uracils but has no effect on methylated cytosines. This 
conversion can then be exploited in a sequencing context because cytosines that were originally 
unmethylated will appear as thymines after amplification and those that were methylated will remain 
cytosines. The net effect of this conversion process is that the complexity of the genome is greatly 
reduced since consequently the genome now consists of three bases instead of four with the exception 
of methylated cytosines. Bias may be introduced in site specific methods due to incomplete bisulfite 
conversion and the efficiency of bisulfite PCR. These methods also require extensive bioinformatics 
for aligning the resulting sequences to the bisulfite converted genome and therefore may not be a 
suitable option for laboratories that do not have bioinformatic support.  
Alternately, affinity based methods enrich for the methylated fraction of the genome by “pulling 
down” methylated DNA fragments. These methods are limited by the sensitivity and specificity of the 
antibody or binding protein employed. In general, these methods are more effective in enriching for 
regions of the genome with a high density of methylation and less efficient in CpG poor regions of the 
genome. Given that highly repetitive sequences are densely methylated, a considerable proportion of 
the sequences generated may be impossible to unambiguously align to the genome.  In addition, 
digestion with methylation sensitive or methylation dependent enzymes enrich for the unmethylated or 
methylated regions of the genome respectively.  When combined with NGS fragments that are 
‘missing’ after digestion with a methylation sensitive enzyme represent the methylated regions of the 
genome while those that are present after digestion with a methylation dependent enzyme represent the 
methylated regions of the genome. Because the affinity and restriction enzyme methods confer only 
regional methylation information, additional experiments are needed to identify the precise location of 
CpG methylation within these regions. 
3.1. Site specific  
Whole-genome bisulfite sequencing provides coverage at single base pair resolution and is therefore 
the most comprehensive of the site specific methodologies. In this method the DNA is sheared and 
bisulfite  adaptors are ligated to the fragments.  These  adaptors can be synthesized with   
5-methylcytosine so that the cytosines remain cytosines after bisulfite conversion or alternatively one 
can use modified amplification primers to include the bisulfite converted version of the adaptor. It is 
important to note that the sequence of the adaptors after bisulfite conversion must be complimentary to 
the seeding oligos. Therefore, it is imperative that the cytosines are preserved after conversion in order 
for the fragments to be clonally amplified on a flow cell. After the adaptors are added, the sample is 
bisulfite converted and the converted fragments are PCR amplified. These amplified fragments are 
then used in the library preparation for high throughput sequencing. In 2008, Cokus and colleagues 
published the complete methylome of Arabidopsis using this technique coupled with the Illumina GA Genes 2010, 1                              
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sequencing platform [33]. This technology produced 3.8 billion high quality nucleotides providing 
20X coverage of the 120 Mb Arabidopsis genome. Of these, 2.6 billion nucleotides mapped uniquely 
to the genome and covered 93% of all cytosines that could be theoretically covered. The size of the 
Arabidopsis genome makes it amenable to this type of study, however, the size of the human genome 
is approximately 150X larger than the Arabidopsis genome and therefore performing these 
experiments in human (or other mammals for that matter) is cost prohibitive at this time. Nonetheless, 
this technology was used by Laurent and colleagues to compare human cell types at three progressive 
stages of differentiation [41] and by Lister and colleagues to compare human embryonic stem cells and 
fetal fibroblasts [23]. To date, the only other group to use the shot-gun bisulfite sequencing approach 
constructed an Escherichia coli methylome using the SOLiD
TM platform [39]. Whole-genome bisulfite 
sequencing provides unbiased coverage of the genome allowing for the interrogation of regions of the 
genome that are often missed using other methodologies. 
While bisulfite treatment followed by shotgun sequencing remains a daunting task for large 
genomes, there are methods available that enrich CpG fragments which greatly reduces the depth of 
sequencing required for whole-genome coverage. Some of these methods are technically challenging 
and each has unique biases that are introduced. Reduced representation bisulfite sequencing, targeted 
capture and padlock probes are described in the following sections.  
Reduced representation bisulfite sequencing (RRBS) enriches for CpG rich regions of the genome 
without the need for a known set of targets (i.e., candidate genes, CpG islands, promoters, enhancers 
etc.).  In this method DNA is fragmented with a restriction enzyme (or combination of enzymes), 
adaptors are ligated to size selected fragments then bisulfite treated and amplified to produce a library 
for NGS (Figure 2A). Enrichment using restriction enzymes is not truly genome-wide but includes a 
large portion of the genome and has the advantage of targeting non-repetitive CpG containing regions 
of the genome. The data generated includes regions of the genome that are in close proximity to a 
specific restriction enzyme’s recognition sequence. This is helpful in  regards to the bioinformatic 
analysis of these data because the genome is reduced  and therefore less computational power  is 
required to align the sequences. In choosing the appropriate enzyme to use to reduce the genome to be 
sequenced, one must consider which NGS platform will be used since each sequencing platform has 
unique properties. For example the Illumina and Applied Biosystems platforms produce short sequence 
reads and therefore the size of the restriction fragment produced should remain small while 454 can 
handle longer fragments and to reach its full potential restriction enzymes that result in larger 
fragments should be chosen in order to cover as much of the genome as possible.  
Meissner and colleagues first published the concept of RRBS in 2005 [42]. After the restriction of 
mouse DNA with BglII (recognition sequence AGATCT), fragments between 500 and 600 bp were 
size selected and then adaptors were ligated to the size selected fragments. The fragments were then 
subjected to bisulfite treatment, amplified using bisulfite-modified adaptor sequences, cloned into a 
plasmid vector and then sequenced using conventional Sanger sequencing. To align the data, the 
generated sequences were searched against a reduced representation database of in silico size selected 
and bisulfite treated BglII fragments. This method was modified in 2009 by Meissner’s group for 
amenability to the Illumina sequencing platform [43]. In this protocol MspI, a methylation insensitive 
enzyme, was used to digest mouse DNA. The use of this particular enzyme ensures that at least two 
data points will be produced for each restriction fragment since the MspI recognition sequence is Genes 2010, 1                              
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CCGG. The resulting fragments were end repaired and then methylated adaptor sequences were ligated 
to the fragments. The adaptor-ligated fragments were size selected for 40-120 bp and 120-220 bp and 
two sequencing libraries were produced. The selected fragments were bisulfite converted and then 
amplified to produce  two  sequencing libraries instead of a single library to reduce size related 
amplification bias.  
Figure 2.  Site specific NGS methodologies. A.  Reduced representation bisulfite 
sequencing (RRBS). B.  Padlock probe assisted multiplex amplification. NGS: Next 
generation sequencing. 
 
 
In addition to using single enzymes for RRBS, combinations of enzymes can also be used. Zeshnigk 
and colleagues used MseI (TTAA) and Tsp509I (AATT) to deplete AT rich regions of the genome in 
combination with NlaIII (CATG) and HpyCH4 (TGCA) [44]. After digestion, adaptors were ligated to 
blunt-ended and phosphorylated fragments. The adaptor-ligated fragments were treated with bisulfite, 
amplified and then size selected (440-900 bp) before sequencing using the 454 GS FLX. This study 
compared the methylation present in human female white blood cells with the methylation present in 
human sperm. Theoretically this combination of enzymes should produce data that covers 12,482 CGI 
(~45% of annotated CGI); however, only 21-22% of annotated CGI were covered and only 7.6% and 
7.9% of the female white blood cell and sperm cell reads respectively mapped to a CGI. While this 
may be an effective enrichment strategy, these results suggest that this library preparation method is Genes 2010, 1                              
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biased toward non-CG rich regions; however, it may be possible to increase the CGI coverage by 
obtaining more sequence reads.  
Targeted capture microarrays comprised of probes that encompass regions of interest or targeted 
probe libraries within solution can be used to enrich for regions of the genome before sequencing. 
Targeted probes can be developed to capture bisulfite converted or non-converted sequences. An 
important consideration, if the bisulfite converted genome is the targeted genome, is that capture 
probes must be designed such that all permutations after bisulfite conversion are included. A clear 
advantage to this method is that it provides a reduced genome without the sequence constraint inherent 
in RRBS which utilizes restriction enzymes. In 2009 Hodges and colleagues published a method for 
targeting bisulfite converted DNA to enrich for regions of interest in the genome [32]. In this method, 
genomic DNA was sonicated and then methylated Illumina adaptors were ligated to the fragments. The 
fragments were then size selected (200-300 bp) and bisulfite converted. The converted templates were 
PCR amplified and captured on a custom Agilent 244 k array. The captured fragments were then eluted 
and sequenced using the Illumina GA platform. These authors sequenced a normal and a cancer cell 
line and report an enrichment of over 700 fold in the normal cell line and over 1300 fold in the cancer 
cell line. In both cell lines more than 90% of the target region was covered by at least 10 sequencing 
reads. However, only 6.43% of the total reads in the normal cell line and 11.98% of the total reads in 
the cancer cell line mapped to the targeted region. Therefore, a disadvantage of this method is that the 
capture is often imprecise and fairly inefficient. On the other hand, because an amplification step is 
required in this protocol, less DNA is required as starting material than is needed for arrays targeted at 
non-bisulfite converted DNA. 
Padlock probe assisted multiplex amplification is performed in solution and has the capability of 
targeting more of the genome than the current array based capture platforms. Padlock probes are 
designed such that a region of interest  is covered by overlapping probes on both the sense and 
antisense DNA strand (Figure 2B). Each probe consists of two target specific arms connected by a 
universal backbone sequence and hybridizes to the DNA in two places leaving the backbone sequence 
unbound. The gap between the two arms is polymerized and then ligated to form circular DNA. The 
backbone sequence is then used for universal PCR allowing for the amplification of tens of thousands 
of probes within a single reaction. Extensive bioinformatics is required for the design of the padlock 
probes because each probe must be normalized for melting temperature and length. Recently, two 
groups utilized this technology for methylation analysis. In each case, a library of padlock probes was 
annealed to bisulfite converted DNA. Next the 3’ ends were extended and ligated to the 5’ ends. The 
linear DNA was removed by exonucleases and then the circularized DNA was amplified with common 
primers. Deng and colleagues developed padlock probes to capture 175-225 bp regions including CpG 
islands, promoters and the transcription start site of genes involved in development or pluripotency 
[30]. In total 10,582 probes were required to cover 2.1 Mbp of the genome. However, since bisulfite 
conversion results in all unmethylated cytosines being converted to uracils, 30,000 probes were 
developed in which all C/T combinations were included for those probes that contained CpG sites. 
They observed a 10,000 fold difference in capture efficiencies between the most and the least efficient 
probes. Therefore, some probes required re-synthesis (to gain efficiency) and some probes required the 
addition of suppressor oligos (to reduce efficiency) which is the primary shortcoming of this method. 
Ball  and colleagues  focused on the ENCODE pilot project regions  and avoided CpGs in the Genes 2010, 1                              
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hybridizing arms so that only one probe was necessary per locus [36]. Their design targeted regions of 
the genome that are not associated with CGI and therefore provide data from regions not typically 
included in methylation studies. 
3.2. Regional 
Restriction-enzyme methods create a genome-wide methylation profile for regions of the genome 
that are encompassed by DNA fragments created after digestion with either a methylation sensitive or 
methylation dependent enzyme (or combination of enzymes).  Ball and colleagues utilized the 
methylation sensitive enzyme HpaII to create a library of tag fragments that were then sequenced using 
the Illumina platform [45]. In this method, a library of tag fragments from all restriction fragments was 
created and then subjected to NGS. The methylation of a particular fragment was inferred based on the 
number of times it was observed. For example, fragments that were observed many times had low 
levels of methylation while those that were not observed had high levels of methylation. As a control, 
the authors also created an MspI library which has the same recognition sequence as HpaII but cuts 
either methylated or unmethylated CCGG sequences. After final analysis, the authors concluded that 
the control library was not necessary because the results from the HpaII library alone was highly 
correlated with the methylation present at individual sites. This method is better suited for 
distinguishing between highly and moderately methylated fragments as opposed to moderately and 
weakly methylated fragments because there is more noise associated with the weakly methylated (and 
therefore more highly digested) fragments. Concurrently, a second group published a modification of 
the HpaII tiny fragment enrichment ligation mediated PCR (HELP) protocol, HELP-seq [46]. For this 
method, the authors removed the adaptors from the LM-PCR products with MspI and then used the 
fragments to create sequencing libraries. The results of HELP-seq and HELP with microarray were 
compared and found to be strongly concordant. However, HELP-seq identified more hypomethylated 
loci and allowed the identification of shorter sequences that were not able to be represented on the 
microarray. In 2009, Wang and colleagues used a methylation dependent enzyme McrBC to identify 
methylation in the maize genome [47]. Cleavage with McrBC requires the presence of two methylated 
recognition sequences separated by 40-3000 base pairs. In this method, genomic DNA was digested 
with McrBC and then size selected fragments were used for library construction and then sequenced 
using the Illumina platform. Restriction based methods provide an excellent initial screen of the 
genome but are biased toward regions of the genome that  contain restriction enzyme recognition 
sequences and require additional experiments to determine the precise location of methylated cytosines 
within the methylated fragments.  
Affinity methods  such as methylated DNA immunoprecipitation (MeDIP) and methylated CpG 
island recovery assay (MIRA)  do not rely on the bisulfite modification of DNA [48,49].  MeDIP 
employs an antibody directed against 5-methylcytosine while MIRA (and modifications of MIRA) 
utilizes methyl-binding proteins (Figure 3). One major difference between the methods is that MeDIP 
requires DNA to be single-stranded in order to achieve  efficient pull down which is sometimes 
difficult to achieve in regions of high CpG content and MIRA does not. Both MeDIP and MIRA can 
now be performed using commercial kits available from multiple companies. Briefly, for MeDIP, the 
DNA is sheared into 300-1 kb fragments, denatured and incubated with anti-5 methyl-cytosine.  Genes 2010, 1                              
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Figure 3. Affinity-based methodologies. MeDIP: Methylated DNA immunoprecipitation; 
MIRA: Methylated CGI recovery assay; MBD: Methyl-binding domain. 
 
 
Magnetic or agarose (sepharose) beads are added and the methylated DNA is separated from the 
unmethylated DNA. Recently, Butcher and Beck published a modified version of this protocol 
amenable to high-throughput methylome analysis termed AutoMeDIP-seq  [50].  In MIRA, a   
His-tagged MBD2b/MBD3L1 complex is incubated with DNA fragmented either by shearing or by 
digestion with MseI. The methylated protein-DNA complexes are captured using magnetic beads and 
the DNA is eluted while the protein complexes are degraded. A modification of this technique was 
recently used to characterize the methylome of three cancer cell lines and termed methyl binding 
domain (MBD) isolated genome sequencing [51]. Bioinformatic analysis of data generated after 
affinity enrichment is complicated by the need to take into consideration the density of CpG 
dinucleotides in a given region and by the inherent enrichment of repeat regions which can be difficult 
or even impossible to align to the genome.  Overall, affinity methods provide a genome-wide 
assessment of the methylation present but do not give information on specific CpG dinucleotides and 
are biased toward CG rich regions of the genome.  
4. Progress Toward Characterizing the Methylome of Lymphoma and Leukemia  
4.1. Genome-wide microarrays 
Genome-wide methylation studies in lymphomas have progressed rapidly in light of the 
development of genome-wide technologies. Some of the earlier microarray platforms allowed for the 
investigation of DNA methylation present within select CpG islands [52,53]. The coverage of these 
arrays was limited but facilitated the discovery of putative tumor suppressor genes that are methylated Genes 2010, 1                              
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in  lymphomas and leukemias. Together with the identification of aberrantly methylated genes, 
investigators were able to differentiate between tumor types and subtypes [54-59] and to identify 
methylation hotspots in the genome [56,60]. The lessons learned from these studies prompted the 
development of commercial arrays that cover CpG islands, promoters of genes and even the whole 
genome (Agilent, Nimblegen Affymetrix, Illumina).  These comprehensive arrays have not only 
allowed investigators to continue to distinguish between disease types, subtypes and outcomes [61-69] 
but have also allowed for the identification of enriched gene pathways and functional groups including 
PRC2 target genes [65,70,71] which has led to a better understanding of the biology of lymphomas and 
leukemias. These discoveries have profound implications with regards to prognosis, diagnosis and 
possibly even treatment of lymphomas and leukemias and highlight the importance of fully elucidating 
epigenomic changes in these disease types.  
4.2. Ultradeep bisulfite NGS of amplicons in B-cell lymphomas 
In 2007 our group developed a novel approach that allowed the simultaneous detection of 
methylation present in the CpG rich region of 25 genes in over 40 cases of primary cells [28]. To 
accomplish this goal, primer sets with disease specific tags on the 5’ end were developed so that after 
NGS the groups could be identified (Figure 4A). Five groups were included, normal peripheral blood 
mononuclear cells (PBMCs),  acute lymphoblastic leukemia  (ALL),  chronic lymphocytic leukemia 
(CLL), follicular lymphoma (FL) and mantle cell lymphoma (MCL). Ten individual samples within 
the same group were pooled together and then bisulfite treated. Gene specific primers containing 
disease specific tags were used to generate 25 amplicons for each group. Using clustering algorithms, 
differential methylation between diseases was shown. While this was not a genome-wide study it 
allowed for deep sequencing of amplicons representing genes whose aberrant methylation was 
previously shown to be methylated in lymphomas or other cancers [55,56,72,73]. Each amplicon was 
sequenced 100-1000 times providing improved statistical power  over that of standard bisulfite 
sequencing. Twenty of the 25 amplicons studied showed an increase in methylation in various diseases 
as compared to PBMCs. Quantitative differences in methylation between diseases were also identified 
and there was a significant increase in the methylation of the 25 amplicons in ALL and FL samples 
compared to CLL and MCL. Unlike methods which provide regional methylation information, this 
method identified the precise location of the methylation present within the promoters of a subset of 
genes. A spreading of methylation was observed from the periphery towards the center of select CpG 
islands in ALL and FL samples.  In addition to generating methylation profiles, deep bisulfite 
sequencing of amplicons allowed for the determination of an association between a SNP and 
methylation and also provided mechanistic insight with regards to the spreading of methylation.  
4.3. RRBS/MIRA plus bisulfite sequencing in a follicular lymphoma cell line: 
In addition to the published work described above, more recently we  developed an approach 
integrating the concept of RRBS with MIRA plus bisulfite conversion to produce a library that was 
sequenced using the 454 GS FLX sequencer (Figure 4B). The inclusion of the enrichment step before 
bisulfite conversion allows for the targeting of methylated regions of the genome but is biased toward 
GC rich DNA sequences. Briefly, genomic DNA was fragmented using Csp6I and then ligated to Genes 2010, 1                              
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adaptors, methylated adaptor-ligated fragments were enriched using a methyl-binding protein and the 
enriched fragments were subjected to bisulfite modification. A sequencing library was constructed and 
the follicular lymphoma cell line, RL, was sequenced. The genome-wide methylation patterns were 
compared with gene expression and histone modification profiles from the same cell line. More than 
11,000 methylated regions of interest (MRI) were identified covering 4033 CpG islands. Methylation 
was detected in members of the HOX clustered genes, the protocadherin cluster, SOX genes and 
Frizzled protein genes and there was a significant overlap in methylation and PRC2 target genes. 
Genome-wide H3K4Me3, H3K27me3 and SUZ12 binding profiles were generated to compare to the 
MRIs identified by NGS. As expected, there was no significant overlap of methylation with H3K4 
trimethylation. There was also no significant overlap of methylation and H3K27 trimethylation or 
SUZ12 binding in  vivo. Furthermore, a SNP in the HLA-A gene cluster was associated with 
methylation status of 2 neighboring CpG sites. The longer bisulfite sequences obtained by 454 
sequencing made sequence alignment accurate and reliable and allowed us to confirm a large number 
of methylated genes in RL cells and to identify distinguishing methylation patterns in the promoters of 
these genes.  
Figure 4.  NGS approaches used to study lymphoid malignancies. A.  Amplicon  deep-
sequencing. ALL: acute lymphoblastic leukemia; CLL: chronic lymphocytic leukemia;   
FL: follicular lymphoma; MCL: mantle cell lymphoma; DST: disease specific tag.  
B. MIRA plus bisulfite conversion. 
 
 
We are at the forefront of exploiting NGS technologies to characterize the methylomes of lymphoid 
malignancies.  The lessons learned and the information amassed from methylation microarrays is 
astounding but progress in this endeavor will increase exponentially now that we have the ability to 
produce true  genome-scale data sets  (Figure 5). The NGS technologies afford the opportunity to Genes 2010, 1                              
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characterize the methylome much more deeply which  is paramount to fully elucidating the 
mechanisms associated with, and the impacts of, aberrant methylation in lymphoid malignancies.  
Figure 5.  Microarray  versus  NGS in lymphoma  methylation studies.  NGS: Next-
generation sequencing; TSG: tumor suppressor gene; SNP: single nucleotide 
polymorphism. * NGS includes all outcomes of microarray in addition to the outcomes 
presented in the diagram. 
 
 
5. Beyond the Methylome 
While DNA methylation was the focus of this review, there are other important epigenetic 
alterations which are also receiving deserving attention. For example, in normal cells, histone 
acetyltransferases (HATs) add acetyl groups to residues on histone tails that leads to a relaxation of the 
chromatin structure, allowing gene transcription to occur. HAT activity is counteracted by histone 
deacetylases (HDACs), enzymes that remove the acetyl groups leading to compaction of nucleosomes 
and transcriptional downregulation. Inhibitors of HDACs (HDACi) are thought to maintain chromatin 
in an open structure and are therefore potential pharmacologic agents because many tumors 
overexpress HDACs and this results in suppression of gene transcription (reviewed in [74]). A number 
of genome-wide studies have identified combinatorial patterns of histone  modifications that may 
correlate with gene structures and functions [75-78].  These studies have mainly addressed the 
processes of acetylation or methylation at lysine (K) or arginine (R) residues in histone protein tails. 
Generally, trimethylation of histone H3K4 is associated with active transcription, while that of H3K27 
is most commonly associated with downregulation, although both marks can appear simultaneously on 
bivalent gene promoters that may be poised for rapid expression or downregulation. 
Certain epigenetic modifications of chromatin by protein arginine methyltransferases (PRMTs) are 
also crucial for normal cell growth and differentiation. The mechanisms controlling this epigenetic 
process are not as well understood compared to lysine methylation. The SWI/SNF-associated protein 
PRMT5 transcriptionally represses its target genes by methylating histone 3 at arginine 8 (H3R8) and 
histone 4 at arginine 3 (H4R3) [79]. PRMT5 protein levels are increased in CLL cell lines secondary to 
the altered expression of PRMT5-specific miRs 19a, 25, 32, 92, 92b, and 96 (discussed below) that Genes 2010, 1                              
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results in an increase of global symmetric methylation of H3R8 and H4R3. An evaluation of both 
epigenetic marks at PRMT5 target genes such as cell cycle pocket proteins RB1 (p105), RBL1 (p107), 
and RBL2 (p130) showed that at their promoters H3R8 and H4R3 are hypermethylated, which then 
leads to transcriptional repression.  Using the human beta-globin locus as a model, symmetric 
dimethylation of H4R3me2 by PRMT5 is required for subsequent DNA methylation [79]. H4R3me2 is 
a direct binding target for DNMT3A, which interacts through the ADD domain containing the PHD 
motif. Loss of the H4R3me2 mark leads to reduced DNMT3A binding, loss of DNA methylation and 
gene activation. Thus, it was proposed that DNMT3A functions as both a reader and a writer of 
repressive epigenetic marks at this locus, thereby directly linking histone and DNA methylation in 
gene silencing. 
Small RNA molecules, referred to as microRNA or miR, act as translational repressors of many 
mRNAs and each may affect hundreds of genes [80]. MiRs are processed after transcription by Drosha 
and Dicer enzymes and ultimately associate with an RNA-induced silencing complex (RISC) that 
binds target mRNAs through partially complementary sequences that then reduce their translation or 
stability. Human miR genes are distributed throughout the genome in a non-random manner and are 
frequently located in chromosomal fragile sites and cancer-associated genomic regions where they 
may act as molecular switches (reviewed in [81,82]). As with other coding genes, miR genes have 
specific functions, and are also susceptible to epigenetic modifications such as DNA hyper-  and 
hypomethylation [83,84]. Some miRs play a fairly direct role in chromatin modification by targeting 
post-transcriptional regulation of key enzymes. For instance, the miR-29 family targets the three main 
DNA methyltransferases of humans either directly or indirectly in lung cancer and acute myeloid 
leukemias [20,21]. These miRs directly target the 3’UTR of DNMT3A and DNMT3B, but affect 
DNMT1 indirectly by targeting SP1 which functions as a transactivator of this enzyme gene. These 
enzymes are clearly important for DNA methylation in all cancers thus far studied. 
6. On the Horizon 
As discussed, the epigenome is comprised of multiple modifications to the genome. Certainly, DNA 
methylation, histone modifications, and miRs are key players, but the global transcriptome is affected 
by many other protein-protein and protein-nucleic acid interactions that in concert can effect changes 
through overall chromatin organization, chromosomal territory localizations, and gene-gene 
interactions through loops of inter-  and intra-chromosomal DNA.  The chromatin state is an 
epigenomic mechanism for wide-spread nuclear activities. For instance, the patterns of euchromatin 
and heterochromatin differ between lymphoma subtypes, as evidenced by electron microscopy.  In 
general, the transcriptionally active euchromatic regions are found near the center of the nucleus, while 
less active heterochromatic regions generally localize near the nuclear membrane. Even beyond the 
visual differences, with the aid of a powerful methods such as Hi-C and formaldehyde-assisted 
isolation of regulatory elements (FAIRE) [85] coupled with genomic sequencing (FAIRE-seq) [86], it 
can been shown that the actual genomic regions and associated genes found in either the euchromatic 
or heterochromatic regions of the nucleus also differ by cell type.  Job Dekker’s laboratory has 
developed multiple methods to probe genomic interactions. The most recent, Hi-C, is a method for 
defining the three-dimensional architecture of entire genomes through proximity-based ligation Genes 2010, 1                              
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followed by massively parallel NGS. Through construction of spatial proximity maps of the human 
genome at a resolution of 1 megabase, they confirmed the presence of chromosome territories and the 
spatial proximity of small, gene-rich chromosomes, as well as an  additional level of genome 
organization characterized by the spatial segregation of euchromatin and heterochromatin to form two 
genome-wide compartments [87]. Thus, Hi-C and NGS can be used to map the dynamic conformations 
of entire genomes. A complementary method, FAIRE-seq, can be used to investigate the genomic 
regions associated with the open chromatin regions of cells. Modifications to this method should also 
allow investigation of the protein-associated DNA found mainly in heterochromatic regions.  It is 
inevitable that further refinements in NGS will facilitate studies at multiple levels of the epigenome 
and chromatin organization that can provide global information affecting the cellular transcriptome, 
proteome, and biological activity that defines clinical behaviors in all types of lymphoma, as well as 
other cancers and normal cells. 
Acknowledgements 
Funding from National Institutes of Health grants CA123018, CA132706 and DA025779 (H. Shi), 
CA100055 and CA097880 (C. Caldwell), CA132784 (K. Taylor) and the CRC Missouri Chair in 
Cancer Research supported much of the data collection on which this review is based. We kindly thank 
Sam I. Hooshmand for assistance in the preparation of the figures included in this review. We also 
thank the reviewers for the thoughtful critiques that improved this manuscript. 
References and Notes 
1.  Egger, G.; Liang, G.; Aparicio, A.; Jones, P.A. Epigenetics in Human Disease and Prospects for 
Epigenetic Therapy. Nature 2004, 429, 457-463. 
2.  Feinberg, A.P.; Ohlsson, R.; Henikoff, S. The Epigenetic Progenitor Origin of Human Cancer. 
Nat. Rev. Genet. 2006, 7, 21-33. 
3.  Laird, P.W. The Power and the Promise of DNA Methylation Markers. Nat. Rev. Cancer 2003, 3, 
253-266. 
4.   Bird, A. DNA Methylation Patterns and Epigenetic Memory. Genes Dev. 2002, 16, 6-21. 
5.   Robertson, K.D.; Jones, P.A. DNA Methylation: Past, Present and Future Directions. 
Carcinogenesis 2000, 21, 461-467. 
6.   Craig, J.M.; Bickmore, W.A. The Distribution of CpG Islands in Mammalian Chromosomes. Nat. 
Genet. 1994, 7, 376-382. 
7.   Goto, T.; Monk, M. Regulation of X-Chromosome Inactivation in Development in Mice and 
Humans. Microbiol. Mol. Biol. Rev. 1998, 62, 362-378. 
8.   Li, E.; Beard, C.; Jaenisch, R. Role for DNA Methylation in Genomic Imprinting. Nature 1993, 
366, 362-365. 
9.   Razin, A.; Cedar, H. DNA Methylation and Genomic Imprinting. Cell 1994, 77, 473-476. 
10.  Esteller, M. Cancer Epigenomics: DNA Methylomes and Histone-Modification Maps. Nat. Rev. 
Genet. 2007, 8, 286-298. 
11.  Gal-Yam, E.N.; Saito, Y.; Egger, G.; Jones, P.A. Cancer Epigenetics: Modifications, Screening, 
and Therapy. Annu. Rev. Med. 2008, 59, 267-280. Genes 2010, 1                              
 
 
160 
12.  Irizarry, R.A.; Ladd-Acosta, C.; Wen, B.; Wu, Z.; Montano, C.; Onyango, P.; Cui, H.; Gabo, K.; 
Rongione, M.; Webster, M.; et al. The Human Colon Cancer Methylome Shows Similar Hypo- 
and Hypermethylation at Conserved Tissue-Specific CpG Island Shores. Nat. Genet. 2009, 41, 
178-186. 
13.  Bracken, A.P.; Dietrich, N.; Pasini, D.; Hansen, K.H.; Helin, K. Genome-Wide Mapping of 
Polycomb Target Genes Unravels Their Roles in Cell Fate Transitions. Genes Dev. 2006,  20, 
1123-1136. 
14.  Kirmizis, A.; Bartley, S.M.; Kuzmichev, A.; Margueron, R.; Reinberg, D.; Green, R.; Farnham, 
P.J. Silencing of Human Polycomb Target Genes Is Associated With Methylation of Histone H3 
Lys 27. Genes Dev. 2004, 18, 1592-1605. 
15.  Lee, M.G.; Villa, R.; Trojer, P.; Norman, J.; Yan, K.P.; Reinberg, D.; Di, C.L.; Shiekhattar, R. 
Demethylation of H3K27 Regulates Polycomb Recruitment and H2A Ubiquitination. Science 
2007, 318, 447-450. 
16.  Raaphorst, F.M. Deregulated Expression of Polycomb-Group Oncogenes in Human Malignant 
Lymphomas and Epithelial Tumors. Hum. Mol. Genet. 2005, 14, R93-R100. 
17.  Schlesinger, Y.; Straussman, R.; Keshet, I.; Farkash, S.; Hecht, M.; Zimmerman, J.; Eden, E.; 
Yakhini, Z.; Ben-Shushan, E.; Reubinoff, B.E.; Bergman, Y.; Simon, I.; Cedar, H. Polycomb-
Mediated Methylation on Lys27 of Histone H3 Pre-Marks Genes for De Novo Methylation in 
Cancer. Nat. Genet. 2007, 39, 232-236. 
18.  Vire, E.; Brenner, C.; Deplus, R.; Blanchon, L.; Fraga, M.; Didelot, C.; Morey, L.; Van, E.A.; 
Bernard, D.; Vanderwinden, J.M.; et al. The Polycomb Group Protein EZH2 Directly Controls 
DNA Methylation. Nature 2005, 439, 871-874. 
19.  Ng, E.K.; Tsang, W.P.; Ng, S.S.; Jin, H.C.; Yu, J.; Li, J.J.; Rocken, C.; Ebert, M.P.; Kwok, T.T.; 
Sung, J.J. MicroRNA-143 Targets DNA Methyltransferases 3A in Colorectal Cancer. Br. J. 
Cancer 2009, 101, 699-706. 
20.  Fabbri, M.; Garzon, R.; Cimmino, A.; Liu, Z.; Zanesi, N.; Callegari, E.; Liu, S.; Alder, H.; 
Costinean, S.; Fernandez-Cymering, C.; et al.  MicroRNA-29 Family Reverts Aberrant 
Methylation in Lung Cancer by Targeting DNA Methyltransferases 3A and 3B. Proc. Natl. Acad. 
Sci. U. S. A. 2007, 104, 15805-15810. 
21.  Garzon, R.; Liu, S.; Fabbri, M.; Liu, Z.; Heaphy, C.E.; Callegari, E.; Schwind, S.; Pang, J.; Yu, J.; 
Muthusamy, N.; et al.  MicroRNA-29b Induces Global DNA Hypomethylation and Tumor 
Suppressor Gene Reexpression in Acute Myeloid Leukemia by Targeting Directly DNMT3A and 
3B and Indirectly DNMT1. Blood 2009, 113, 6411-6418. 
22.  Laird, P.W. Principles and Challenges of Genome-Wide DNA Methylation Analysis. Nat. Rev. 
Genet. 2010, 11, 191-203. 
23.  Lister, R.; Pelizzola, M.; Dowen, R.H.; Hawkins, R.D.; Hon, G.; Tonti-Filippini, J.; Nery, J.R.; 
Lee, L.; Ye, Z.; Ngo, Q.M.; et al. Human DNA Methylomes at Base Resolution Show Widespread 
Epigenomic Differences. Nature 2009, 462, 315-322. 
24.  Metzker, M.L. Sequencing Technologies - the Next Generation. Nat. Rev. Genet. 2010, 11, 31-46. 
25.  Mardis, E.R. The Impact of Next-Generation Sequencing Technology on Genetics. Trends Genet. 
2008, 24, 133-141. Genes 2010, 1                              
 
 
161 
26.  Korshunova, Y.; Maloney, R.K.; Lakey, N.; Citek, R.W.; Bacher, B.; Budiman, A.; Ordway, J.M.; 
McCombie, W.R.; Leon, J.; Jeddeloh, J.A.; McPherson, J.D. Massively Parallel Bisulphite 
Pyrosequencing Reveals the Molecular Complexity of Breast Cancer-Associated Cytosine-
Methylation Patterns Obtained From Tissue and Serum DNA. Genome Res. 2008, 18, 19-29. 
27.  Ordway, J.M.; Budiman, M.A.; Korshunova, Y.; Maloney, R.K.; Bedell, J.A.; Citek, R.W.; 
Bacher, B.; Peterson, S.; Rohlfing, T.; Hall, J.; Brown, R.; Lakey, N.; Doerge, R.W.; Martienssen, 
R.A.; Leon, J.; McPherson, J.D.; Jeddeloh, J.A. Identification of Novel High-Frequency DNA 
Methylation Changes in Breast Cancer. PLoS. One 2007, 2, e1314. 
28.  Taylor, K.H.; Kramer, R.S.; Davis, J.W.; Guo, J.; Duff, D.J.; Xu, D.; Caldwell, C.W.; Shi, H. 
Ultradeep Bisulfite Sequencing Analysis of DNA Methylation Patterns in Multiple Gene 
Promoters by 454 Sequencing. Cancer Res. 2007, 67, 8511-8518. 
29.  Xie, H.; Wang, M.; Bonaldo, M.F.; Rajaram, V.; Stellpflug, W.; Smith, C.; Arndt, K.; Goldman, 
S.; Tomita, T.; Soares, M.B. Epigenomic Analysis of Alu Repeats in Human Ependymomas. 
Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 6952-6957. 
30.  Deng, J.; Shoemaker, R.; Xie, B.; Gore, A.; LeProust, E.M.; ntosiewicz-Bourget, J.; Egli, D.; 
Maherali, N.; Park, I.H.; Yu, J.; Daley, G.Q.; Eggan, K.; Hochedlinger, K.; Thomson, J.; Wang, 
W.; Gao, Y.; Zhang, K. Targeted Bisulfite Sequencing Reveals Changes in DNA Methylation 
Associated With Nuclear Reprogramming. Nat. Biotechnol. 2009, 27, 353-360. 
31.  Gu, H.; Bock, C.; Mikkelsen, T.S.; Jager, N.; Smith, Z.D.; Tomazou, E.; Gnirke, A.; Lander, E.S.; 
Meissner, A. Genome-Scale DNA Methylation Mapping of Clinical Samples at Single-Nucleotide 
Resolution. Nat. Methods 2010, 7, 133-136. 
32.  Hodges, E.; Smith, A.D.; Kendall, J.; Xuan, Z.; Ravi, K.; Rooks, M.; Zhang, M.Q.; Ye, K.; 
Bhattacharjee, A.; Brizuela, L.; et al. High Definition Profiling of Mammalian DNA Methylation 
by Array Capture and Single Molecule Bisulfite Sequencing. Genome Res. 2009, 19, 1593-1605. 
33.  Cokus, S.J.; Feng, S.; Zhang, X.; Chen, Z.; Merriman, B.; Haudenschild, C.D.; Pradhan, S.; 
Nelson, S.F.; Pellegrini, M.; Jacobsen, S.E. Shotgun Bisulphite Sequencing of the Arabidopsis 
Genome Reveals DNA Methylation Patterning. Nature 2008, 452, 215-219. 
34.  Feng, S.; Cokus, S.J.; Zhang, X.; Chen, P.Y.; Bostick, M.; Goll, M.G.; Hetzel, J.; Jain, J.; Strauss, 
S.H.; Halpern, M.E.; Ukomadu, C.; Sadler, K.C.; Pradhan, S.; Pellegrini, M.; Jacobsen, S.E. 
Conservation and Divergence of Methylation Patterning in Plants and Animals. Proc. Natl. Acad. 
Sci. U. S. A. 2010, 107, 8689-8694. 
35.  Lister, R.; O'Malley, R.C.; Tonti-Filippini, J.; Gregory, B.D.; Berry, C.C.; Millar, A.H.; Ecker, 
J.R. Highly Integrated Single-Base Resolution Maps of the Epigenome in Arabidopsis. Cell 2008, 
133, 523-536. 
36.  Ball, M.P.; Li, J.B.; Gao, Y.; Lee, J.H.; LeProust, E.M.; Park, I.H.; Xie, B.; Daley, G.Q.; Church, 
G.M. Targeted and Genome-Scale Strategies Reveal Gene-Body Methylation Signatures in 
Human Cells. Nat. Biotechnol. 2009, 27, 361-368. 
37.  Li, J.; Gao, F.; Li, N.; Li, S.; Yin, G.; Tian, G.; Jia, S.; Wang, K.; Zhang, X.; Yang, H.; Nielsen, 
A.L.; Bolund, L. An Improved Method for Genome Wide DNA Methylation Profiling Correlated 
to Transcription and Genomic Instability in Two Breast Cancer Cell Lines. BMC Genomics 2009, 
10, 223. Genes 2010, 1                              
 
 
162 
38.  Shendure, J.; Porreca, G.J.; Reppas, N.B.; Lin, X.; McCutcheon, J.P.; Rosenbaum, A.M.; Wang, 
M.D.; Zhang, K.; Mitra, R.D.; Church, G.M. Accurate Multiplex Polony Sequencing of an 
Evolved Bacterial Genome. Science 2005, 309, 1728-1732. 
39.  Bormann Chung, C.A.; Boyd, V.L.; McKernan, K.J.; Fu, Y.; Monighetti, C.; Peckham, H.E.; 
Barker, M. Whole Methylome Analysis by Ultra-Deep Sequencing Using Two-Base Encoding. 
PLoS One 2010, 5, e9320. 
40.  Drmanac, R.; Sparks, A.B.; Callow, M.J.; Halpern, A.L.; Burns, N.L.; Kermani, B.G.; Carnevali, 
P.; Nazarenko, I.; Nilsen, G.B.; Yeung, G.; et al. Human Genome Sequencing Using Unchained 
Base Reads on Self-Assembling DNA Nanoarrays. Science 2010, 327, 78-81. 
41.  Laurent, L.; Wong, E.; Li, G.; Huynh, T.; Tsirigos, A.; Ong, C.T.; Low, H.M.; Kin Sung, K.W.; 
Rigoutsos, I.; Loring, J.; Wei, C.L. Dynamic Changes in the Human Methylome During 
Differentiation. Genome Res. 2010, 20, 320-331. 
42.  Meissner, A.; Gnirke, A.; Bell, G.W.; Ramsahoye, B.; Lander, E.S.; Jaenisch, R. Reduced 
Representation Bisulfite Sequencing for Comparative High-Resolution DNA Methylation 
Analysis. Nucleic Acids Res. 2005, 33, 5868-5877. 
43.  Smith, Z.D.; Gu, H.; Bock, C.; Gnirke, A.; Meissner, A. High-Throughput Bisulfite Sequencing in 
Mammalian Genomes. Methods 2009, 48, 226-232. 
44.  Zeschnigk, M.; Martin, M.; Betzl, G.; Kalbe, A.; Sirsch, C.; Buiting, K.; Gross, S.; Fritzilas, E.; 
Frey, B.; Rahmann, S.; Horsthemke, B. Massive Parallel Bisulfite Sequencing of CG-Rich DNA 
Fragments Reveals That Methylation of Many X-Chromosomal CpG Islands in Female Blood 
DNA Is Incomplete. Hum. Mol. Genet. 2009, 18, 1439-1448. 
45.  Birney, E.; Stamatoyannopoulos, J.A.; Dutta, A.; Guigo, R.; Gingeras, T.R.; Margulies, E.H.; 
Weng, Z.; Snyder, M.; Dermitzakis, E.T.; Thurman, R.E.; et al. Identification and Analysis of 
Functional Elements in 1% of the Human Genome by the ENCODE Pilot Project. Nature 2007, 
447, 799-816. 
46.  Oda, M.; Glass, J.L.; Thompson, R.F.; Mo, Y.; Olivier, E.N.; Figueroa, M.E.; Selzer, R.R.; 
Richmond, T.A.; Zhang, X.; Dannenberg, L.; et al.  High-Resolution Genome-Wide Cytosine 
Methylation Profiling With Simultaneous Copy Number Analysis and Optimization for Limited 
Cell Numbers. Nucleic Acids Res. 2009, 37, 3829-3839. 
47.  Wang, X.; Elling, A.A.; Li, X.; Li, N.; Peng, Z.; He, G.; Sun, H.; Qi, Y.; Liu, X.S.; Deng, X.W. 
Genome-Wide and Organ-Specific Landscapes of Epigenetic Modifications and Their 
Relationships to MRNA and Small RNA Transcriptomes in Maize. Plant Cell 2009,  21,  
1053-1069. 
48.  Rauch, T.; Pfeifer, G.P. Methylated-CpG Island Recovery Assay: a New Technique for the Rapid 
Detection of Methylated-CpG Islands in Cancer. Lab. Invest. 2005, 85, 1172-1180. 
49.  Weber, M.; Davies, J.J.; Wittig, D.; Oakeley, E.J.; Haase, M.; Lam, W.L.; Schubeler, D. 
Chromosome-Wide and Promoter-Specific Analyses Identify Sites of Differential DNA 
Methylation in Normal and Transformed Human Cells. Nat. Genet. 2005, 37, 853-862. 
50.  Butcher, L.M.; Beck, S. AutoMeDIP-Seq: A High-Throughput, Whole Genome, DNA 
Methylation Assay. Methods  2010,  Available online: 
http://www.ncbi.nlm.nih.gov/pubmed/20385236/. Genes 2010, 1                              
 
 
163 
51.  Serre, D.; Lee, B.H.; Ting, A.H. MBD-Isolated Genome Sequencing Provides a High-Throughput 
and Comprehensive Survey of DNA Methylation in the Human Genome. Nucleic Acids Res. 
2010, 38, 391-399. 
52.  Heisler, L.E.; Torti, D.; Boutros, P.C.; Watson, J.; Chan, C.; Winegarden, N.; Takahashi, M.; Yau, 
P.; Huang, T.H.; Farnham, P.J.; Jurisica, I.; Woodgett, J.R.; Bremner, R.; Penn, L.Z.; Der, S.D. 
CpG Island Microarray Probe Sequences Derived From a Physical Library Are Representative of 
CpG Islands Annotated on the Human Genome. Nucleic Acids Res. 2005, 33, 2952-2961. 
53.  Yan, P.S.; Chen, C.M.; Shi, H.; Rahmatpanah, F.; Wei, S.H.; Caldwell, C.W.; Huang, T.H. 
Dissecting Complex Epigenetic Alterations in Breast Cancer Using CpG Island Microarrays. 
Cancer Res. 2001, 61, 8375-8380. 
54.  Guo, J.; Burger, M.; Nimmrich, I.; Maier, S.; Becker, E.; Genc, B.; Duff, D.; Rahmatpanah, F.; 
Chitma-Matsiga, R.; Shi, H.; Berlin, K.; Huang, T.H.; Caldwell, C.W. Differential DNA 
Methylation of Gene Promoters in Small B-Cell Lymphomas. Am. J. Clin. Pathol. 2005, 124,  
430-439. 
55.  Shi, H.; Guo, J.; Duff, D.J.; Rahmatpanah, F.; Chitima-Matsiga, R.; Al-Kuhlani, M.; Taylor, K.H.; 
Sjahputera, O.; Andreski, M.; Wooldridge, J.E.; Caldwell, C.W. Discovery of Novel Epigenetic 
Markers in Non-Hodgkin's Lymphoma. Carcinogenesis 2007, 28, 60-70. 
56.  Taylor, K.H.; Pena-Hernandez, K.E.; Davis, J.W.; Arthur, G.L.; Duff, D.J.; Shi, H.; Rahmatpanah, 
F.B.; Sjahputera, O.; Caldwell, C.W. Large-Scale CpG Methylation Analysis Identifies Novel 
Candidate Genes and Reveals Methylation Hotspots in Acute Lymphoblastic Leukemia. Cancer 
Res. 2007, 67, 2617-2625. 
57.  van, D.R.; Zoutman, W.H.; Dijkman, R.; de Menezes, R.X.; Commandeur, S.; Mulder, A.A.; van, 
d., V; Vermeer, M.H.; Willemze, R.; Yan, P.S.; Huang, T.H.; Tensen, C.P. Epigenetic Profiling of 
Cutaneous T-Cell Lymphoma: Promoter Hypermethylation of Multiple Tumor Suppressor Genes 
Including BCL7a, PTPRG, and P73. J. Clin. Oncol. 2005, 23, 3886-3896. 
58.  Scholz, C.; Nimmrich, I.; Burger, M.; Becker, E.; Dorken, B.; Ludwig, W.D.; Maier, S. 
Distinction of Acute Lymphoblastic Leukemia From Acute Myeloid Leukemia Through 
Microarray-Based DNA Methylation Analysis. Ann. Hematol. 2005, 84, 236-244. 
59.  Martin-Subero, J.I.; Ammerpohl, O.; Bibikova, M.; Wickham-Garcia, E.; Agirre, X.; Alvarez, S.; 
Bruggemann, M.; Bug, S.; Calasanz, M.J.; Deckert, M.; et al. A Comprehensive Microarray-
Based DNA Methylation Study of 367 Hematological Neoplasms. PLoS. One. 2009, 4, e6986. 
60.  Taylor, K.H.; Rahmatpanah, F.; Davis, J.W.; Caldwell, C.W. Chromosomal Localization of DNA 
Methylation in Small B-Cell Lymphoma. Leukemia 2007, 22, 638-641. 
61.  Davidsson, J.; Lilljebjorn, H.; Andersson, A.; Veerla, S.; Heldrup, J.; Behrendtz, M.; Fioretos, T.; 
Johansson, B. The DNA Methylome of Pediatric Acute Lymphoblastic Leukemia. Hum. Mol. 
Genet. 2009, 18, 4054-4065. 
62.  Figueroa, M.E.; Reimers, M.; Thompson, R.F.; Ye, K.; Li, Y.; Selzer, R.R.; Fridriksson, J.; 
Paietta, E.; Wiernik, P.; Green, R.D.; Greally, J.M.; Melnick, A. An Integrative Genomic and 
Epigenomic Approach for the Study of Transcriptional Regulation. PLoS One 2008, 3, e1882. 
   Genes 2010, 1                              
 
 
164 
63.  Figueroa, M.E.; Wouters, B.J.; Skrabanek, L.; Glass, J.; Li, Y.; Erpelinck-Verschueren, C.A.; 
Langerak, A.W.; Lowenberg, B.; Fazzari, M.; Greally, J.M.; Valk, P.J.; Melnick, A.; Delwel, R. 
Genome-Wide Epigenetic Analysis Delineates a Biologically Distinct Immature Acute Leukemia 
With Myeloid/T-Lymphoid Features. Blood 2009, 113, 2795-2804. 
64.  Kanduri, M.; Cahill, N.; Goransson, H.; Enstrom, C.; Ryan, F.; Isaksson, A.; Rosenquist, R. 
Differential Genome-Wide Array-Based Methylation Profiles in Prognostic Subsets of Chronic 
Lymphocytic Leukemia. Blood 2010, 115, 296-305. 
65.  Martin-Subero, J.I.; Kreuz, M.; Bibikova, M.; Bentink, S.; Ammerpohl, O.; Wickham-Garcia, E.; 
Rosolowski, M.; Richter, J.; Lopez-Serra, L.; Ballestar, E.; et al. New Insights into the Biology 
and Origin of Mature Aggressive B-Cell Lymphomas by Combined Epigenomic, Genomic, and 
Transcriptional Profiling. Blood 2009, 113, 2488-2497. 
66.  Deneberg, S.; Grovdal, M.; Karimi, M.; Jansson, M.; Nahi, H.; Corbacioglu, A.; Gaidzik, V.; 
Dohner, K.; Paul, C.; Ekstrom, T.J.; Hellstrom-Lindberg, E.; Lehmann, S. Gene-Specific and 
Global Methylation Patterns Predict Outcome in Patients With Acute Myeloid Leukemia. 
Leukemia 2010, 24, 932-941. 
67.  Dunwell, T.; Hesson, L.; Rauch, T.A.; Wang, L.; Clark, R.E.; Dallol, A.; Gentle, D.; Catchpoole, 
D.; Maher, E.R.; Pfeifer, G.P.; Latif, F. A Genome-Wide Screen Identifies Frequently Methylated 
Genes in Haematological and Epithelial Cancers. Mol. Cancer 2010, 9, 44. 
68.  Schafer, E.; Irizarry, R.; Negi, S.; McIntyre, E.; Small, D.; Figueroa, M.E.; Melnick, A.; Brown, 
P. Promoter Hypermethylation in MLL-r Infant Acute Lymphoblastic Leukemia: Biology and 
Therapeutic Targeting. Blood 2010, 115, 4798-4809. 
69.  Shaknovich, R.; Figueroa, M.E.; Melnick, A. HELP (HpaII Tiny Fragment Enrichment by 
Ligation-Mediated PCR) Assay for DNA Methylation Profiling of Primary Normal and Malignant 
B Lymphocytes. Methods Mol. Biol. 2010, 632, 191-201. 
70.  Bennett, L.B.; Schnabel, J.L.; Kelchen, J.M.; Taylor, K.H.; Guo, J.; Arthur, G.L.; Papageorgio, 
C.N.; Shi, H.; Caldwell, C.W. DNA Hypermethylation Accompanied by Transcriptional 
Repression in Follicular Lymphoma. Genes Chromosomes Cancer 2009, 48, 828-841. 
71.  Kuang, S.Q.; Bai, H.; Fang, Z.H.; Lopez, G.; Yang, H.; Tong, W.; Wang, Z.Z.; Garcia-Manero, G. 
Aberrant DNA Methylation and Epigenetic Inactivation of Eph Receptor Tyrosine Kinases and 
Ephrin Ligands in Acute Lymphoblastic Leukemia. Blood 2010, 115, 2412-2419. 
72.  Esteller, M. Profiling Aberrant DNA Methylation in Hematologic Neoplasms: a View From the 
Tip of the Iceberg. Clin. Immunol. 2003, 109, 80-88. 
73.  Rahmatpanah, F.B.; Carstens, S.; Guo, J.; Sjahputera, O.; Taylor, K.H.; Duff, D.; Shi, H.; Davis, 
J.W.; Hooshmand,  S.I.; Chitma-Matsiga, R.; Caldwell, C.W. Differential DNA Methylation 
Patterns of Small B-Cell Lymphoma Subclasses With Different Clinical Behavior. Leukemia 
2006, 20, 1855-1862. 
74.  Lane, A.A.; Chabner, B.A. Histone Deacetylase Inhibitors in Cancer Therapy. J. Clin. Oncol. 
2009, 27, 5459-5468. 
75.  Barski, A.; Cuddapah, S.; Cui, K.; Roh, T.Y.; Schones, D.E.; Wang, Z.; Wei, G.; Chepelev, I.; 
Zhao, K. High-Resolution Profiling of Histone Methylations in the Human Genome. Cell 2007, 
129, 823-837. Genes 2010, 1                              
 
 
165 
76.  Bernstein, B.E.; Kamal, M.; Lindblad-Toh, K.; Bekiranov, S.; Bailey, D.K.; Huebert, D.J.; 
McMahon, S.; Karlsson, E.K.; Kulbokas, E.J., III; Gingeras, T.R.; Schreiber, S.L.; Lander, E.S. 
Genomic Maps and Comparative Analysis of Histone Modifications in Human and Mouse. Cell 
2005, 120, 169-181. 
77.  Bernstein, B.E.; Meissner, A.; Lander, E.S. The Mammalian Epigenome. Cell  2007,  128,  
669-681. 
78.  Mikkelsen, T.S.; Ku, M.; Jaffe, D.B.; Issac, B.; Lieberman, E.; Giannoukos, G.; Alvarez, P.; 
Brockman, W.; Kim, T.K.; Koche, R.P.; et al.  Genome-Wide Maps of Chromatin State in 
Pluripotent and Lineage-Committed Cells. Nature 2007, 448, 553-560. 
79.  Zhao, Q.; Rank, G.; Tan, Y.T.; Li, H.; Moritz, R.L.; Simpson, R.J.; Cerruti, L.; Curtis, D.J.; Patel, 
D.J.; Allis, C.D.; Cunningham, J.M.; Jane, S.M. PRMT5-Mediated Methylation of Histone H4R3 
Recruits DNMT3A, Coupling Histone and DNA Methylation in Gene Silencing. Nat. Struct. Mol. 
Biol. 2009, 16, 304-311. 
80.  Ruan, K.; Fang, X.; Ouyang, G. MicroRNAs: Novel Regulators in the Hallmarks of Human 
Cancer. Cancer Lett. 2009, 285, 116-126. 
81.  Garzon, R.; Calin, G.A.; Croce, C.M. MicroRNAs in Cancer. Annu. Rev. Med. 2009, 60, 167-179. 
82.  Sotiropoulou, G.; Pampalakis, G.; Lianidou, E.; Mourelatos, Z. Emerging Roles of MicroRNAs 
As Molecular Switches in the Integrated Circuit of the Cancer Cell. RNA 2009, 15, 1443-1461. 
83.  Weber, B.; Stresemann, C.; Brueckner, B.; Lyko, F. Methylation of Human MicroRNA Genes in 
Normal and Neoplastic Cells. Cell Cycle 2007, 6, 1001-1005. 
84.  Guil, S.; Esteller, M. DNA Methylomes, Histone Codes and MiRNAs: Tying It All Together.  
Int. J. Biochem. Cell Biol. 2009, 41, 87-95. 
85.  Giresi, P.G.; Kim, J.; McDaniell, R.M.; Iyer, V.R.; Lieb, J.D. FAIRE (Formaldehyde-Assisted 
Isolation of Regulatory Elements) Isolates Active Regulatory Elements From Human Chromatin. 
Genome Res. 2007, 17, 877-885. 
86.  Gaulton, K.J.; Nammo, T.; Pasquali, L.; Simon, J.M.; Giresi, P.G.; Fogarty, M.P.; Panhuis, T.M.; 
Mieczkowski, P.; Secchi, A.; Bosco, D.; Berney, T.; Montanya, E.; Mohlke, K.L.; Lieb, J.D.; 
Ferrer, J. A Map of Open Chromatin in Human Pancreatic Islets. Nat. Genet. 2010, 42, 255-259. 
87.  Lieberman-Aiden, E.; van Berkum, N.L.; Williams, L.; Imakaev, M.; Ragoczy, T.; Telling, A.; 
Amit, I.; Lajoie, B.R.; Sabo, P.J.; Dorschner, M.O.; et al. Comprehensive Mapping of Long-
Range Interactions Reveals Folding Principles of the Human Genome.  Science  2009,  326,  
289-293. 
 
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 